标题
Toll-Like Receptor 9 Agonists in Cancer
作者
关键词
-
出版物
OncoTargets and Therapy
Volume Volume 13, Issue -, Pages 10039-10061
出版商
Informa UK Limited
发表日期
2020-10-09
DOI
10.2147/ott.s247050
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study
- (2020) Roy S. Herbst et al. JOURNAL OF CLINICAL ONCOLOGY
- Antibody Opsonization of a TLR9 Agonist–Containing Virus-like Particle Enhances In Situ Immunization
- (2020) Caitlin D. Lemke-Miltner et al. JOURNAL OF IMMUNOLOGY
- Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome
- (2019) Jing Liu et al. OncoImmunology
- A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma
- (2019) Alexander C. Huang et al. NATURE MEDICINE
- The T-cell-inflamed tumor microenvironment as a paradigm for immunotherapy drug development
- (2019) Daniel J Olson et al. Immunotherapy
- Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response
- (2019) J E Stein et al. ANNALS OF ONCOLOGY
- Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
- (2019) O Hamid et al. ANNALS OF ONCOLOGY
- Pathological response and survival with neoadjuvant therapy in melanoma: A pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).
- (2019) Alexander M. Menzies et al. JOURNAL OF CLINICAL ONCOLOGY
- STING pathway agonism as a cancer therapeutic
- (2019) Blake A. Flood et al. IMMUNOLOGICAL REVIEWS
- Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial
- (2019) Elisa A Rozeman et al. LANCET ONCOLOGY
- T‐cell receptor and B‐cell receptor repertoire profiling in adaptive immunity
- (2019) Anastasia Minervina et al. TRANSPLANT INTERNATIONAL
- High tumor mutation burden predicts better efficacy of immunotherapy: a pooled analysis of 103078 cancer patients
- (2019) Dedong Cao et al. OncoImmunology
- Type I interferon suppresses tumor growth through activating the STAT3-granzyme B pathway in tumor-infiltrating cytotoxic T lymphocytes
- (2019) Chunwan Lu et al. Journal for ImmunoTherapy of Cancer
- Release from UNC93B1 reinforces the compartmentalized activation of select TLRs
- (2019) Olivia Majer et al. NATURE
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2019) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV+ oral cancer
- (2019) Stephanie Dorta-Estremera et al. Journal for ImmunoTherapy of Cancer
- Combining alpha radiation-based brachytherapy with immunomodulators promotes complete tumor regression in mice via tumor-specific long-term immune response
- (2019) Vered Domankevich et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
- (2019) Aurelien Marabelle et al. JOURNAL OF CLINICAL ONCOLOGY
- Intratumoral Immunotherapy—Update 2019
- (2019) Omid Hamid et al. ONCOLOGIST
- The Ubiquitin Code of NODs Signaling Pathways in Health and Disease
- (2019) Rubén Julio Martínez-Torres et al. Frontiers in Immunology
- TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma
- (2019) Matthew J. Reilley et al. Journal for ImmunoTherapy of Cancer
- Tumor mutational and indel burden: a systematic pan-cancer evaluation as prognostic biomarkers
- (2019) Hao-Xiang Wu et al. Annals of Translational Medicine
- Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma
- (2018) M T Tetzlaff et al. ANNALS OF ONCOLOGY
- Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)
- (2018) T R Cottrell et al. ANNALS OF ONCOLOGY
- Inhaled TLR9 Agonist Renders Lung Tumors Permissive to PD-1 Blockade by Promoting Optimal CD4+ and CD8+ T cell Interplay
- (2018) Marilena Gallotta et al. CANCER RESEARCH
- Intratumoral CpG-B promotes anti-tumoral neutrophil, cDC, and T cell cooperation without reprograming tolerogenic pDC
- (2018) Marion Humbert et al. CANCER RESEARCH
- The Chaperone UNC93B1 Regulates Toll-like Receptor Stability Independently of Endosomal TLR Transport
- (2018) Karin Pelka et al. IMMUNITY
- Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy
- (2018) Daqing Wang et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- The revival of CpG oligonucleotide-based cancer immunotherapies
- (2018) Tomasz Adamus et al. Wspolczesna Onkologia-Contemporary Oncology
- Toll-like receptor 9 activation by CpG oligodeoxynucleotide�7909 enhances the radiosensitivity of A549 lung cancer cells via the p53 signaling pathway
- (2018) Sujuan Yuan et al. Oncology Letters
- Regulation of C-Type Lectin Receptor-Mediated Antifungal Immunity
- (2018) Juan Tang et al. Frontiers in Immunology
- Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion
- (2018) Flávia Castro et al. Frontiers in Immunology
- Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: Results from the exploratory, controlled, randomized, international phase 2 IMPULSE study
- (2018) M Thomas et al. ANNALS OF ONCOLOGY
- In Situ Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma
- (2018) Matthew J. Frank et al. Cancer Discovery
- SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study
- (2018) Antoni Ribas et al. Cancer Discovery
- T Cell–Inflamed versus Non-T Cell–Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection
- (2018) Jonathan A. Trujillo et al. Cancer Immunology Research
- NOD1 and NOD2 in inflammation, immunity and disease
- (2018) Tapas Mukherjee et al. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
- Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
- (2018) Rodabe N. Amaria et al. NATURE MEDICINE
- Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma
- (2018) Christian U. Blank et al. NATURE MEDICINE
- Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
- (2018) Razvan Cristescu et al. SCIENCE
- Intracerebral injection of CpG oligonucleotide for patients with de novo glioblastoma—A phase II multicentric, randomised study
- (2017) Renata Ursu et al. EUROPEAN JOURNAL OF CANCER
- IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
- (2017) Mark Ayers et al. JOURNAL OF CLINICAL INVESTIGATION
- Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
- (2017) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- An Intraprostatic Modified Release Formulation of Antiandrogen 2-Hydroxyflutamide for Localized Prostate Cancer
- (2017) Teuvo L. Tammela et al. JOURNAL OF UROLOGY
- Type-I-interferons in infection and cancer: Unanticipated dynamics with therapeutic implications
- (2017) Martina Musella et al. OncoImmunology
- Innate immune signaling and regulation in cancer immunotherapy
- (2016) Leticia Corrales et al. CELL RESEARCH
- Structural Analysis Reveals that Toll-like Receptor 7 Is a Dual Receptor for Guanosine and Single-Stranded RNA
- (2016) Zhikuan Zhang et al. IMMUNITY
- Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
- (2016) Antoni Ribas et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma
- (2016) Adil I. Daud et al. JOURNAL OF CLINICAL ONCOLOGY
- TLR10 Is a B Cell Intrinsic Suppressor of Adaptive Immune Responses
- (2016) Nicholas J. Hess et al. JOURNAL OF IMMUNOLOGY
- TLR9 stability and signaling are regulated by phosphorylation and cell stress
- (2016) Maroof Hasan et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+T cells
- (2016) Shu Wang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Open-label phase 1b study of FOLFIRI plus cetuximab plus IMO-2055 in patients with colorectal cancer who have progressed following chemotherapy for advanced or metastatic disease
- (2015) Emily Chan et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: From bench to bedside
- (2015) Burghardt Wittig et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Space and time: New considerations about the relationship between Toll-like receptors (TLRs) and type I interferons (IFNs)
- (2015) Darren J. Perkins et al. CYTOKINE
- Phase I clinical study of the toll-like receptor 9 agonist MGN1703 in patients with metastatic solid tumours
- (2015) Martin R. Weihrauch et al. EUROPEAN JOURNAL OF CANCER
- Structural basis of CpG and inhibitory DNA recognition by Toll-like receptor 9
- (2015) Umeharu Ohto et al. NATURE
- Toll-like receptor 8 senses degradation products of single-stranded RNA
- (2015) Hiromi Tanji et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints
- (2015) M. E. Mikucki et al. Nature Communications
- Toll-like receptor 8 senses degradation products of single-stranded RNA
- (2015) Hiromi Tanji et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Microbiota Modulation of Myeloid Cells in Cancer Therapy
- (2015) R. S. Goldszmid et al. Cancer Immunology Research
- Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma
- (2015) James Larkin et al. JAMA Oncology
- Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy
- (2014) David A. Smith et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
- (2014) J. M. Taube et al. CLINICAL CANCER RESEARCH
- Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial
- (2014) Hans-Joachim Schmoll et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- TLR7 Is Involved in Sequence-Specific Sensing of Single-Stranded RNAs in Human Macrophages
- (2014) M. P. Gantier et al. JOURNAL OF IMMUNOLOGY
- Negative Self-Regulation of TLR9 Signaling by Its N-Terminal Proteolytic Cleavage Product
- (2014) Sungwook Lee et al. JOURNAL OF IMMUNOLOGY
- Determinants of Activity at Human Toll-like Receptors 7 and 8: Quantitative Structure–Activity Relationship (QSAR) of Diverse Heterocyclic Scaffolds
- (2014) Euna Yoo et al. JOURNAL OF MEDICINAL CHEMISTRY
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Toll-like receptor 10 is involved in induction of innate immune responses to influenza virus infection
- (2014) S. M. Y. Lee et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours
- (2013) M Millward et al. BRITISH JOURNAL OF CANCER
- Phase 2 trial of erlotinib with or without PF-3512676 (CPG 7909, a Toll-like receptor 9 agonist) in patients with advanced recurrent EGFR-positive non-small cell lung cancer
- (2013) Chandra P Belani et al. CANCER BIOLOGY & THERAPY
- PD-1 and Tim-3 Regulate the Expansion of Tumor Antigen-Specific CD8+ T Cells Induced by Melanoma Vaccines
- (2013) J. Fourcade et al. CANCER RESEARCH
- Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck
- (2013) Jean-Pascal Machiels et al. INVESTIGATIONAL NEW DRUGS
- Identification of TLR10 as a Key Mediator of the Inflammatory Response to Listeria monocytogenes in Intestinal Epithelial Cells and Macrophages
- (2013) T. Regan et al. JOURNAL OF IMMUNOLOGY
- Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment
- (2013) N. Iida et al. SCIENCE
- Heat shock protein gp96 regulates Toll-like receptor 9 proteolytic processing and conformational stability
- (2012) James C. Brooks et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Pattern recognition receptors—Molecular orchestrators of inflammation in inflammatory bowel disease
- (2012) David Walsh et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8+T-cell responses in melanoma patients
- (2012) Simone M. Goldinger et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Structure-dependent immunostimulatory effect of CpG oligodeoxynucleotides and their delivery system
- (2012) Nobutaka Hanagata International Journal of Nanomedicine
- Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors
- (2012) Hélène Salmon et al. JOURNAL OF CLINICAL INVESTIGATION
- Safety and Immunogenicity of Vaccination With MART-1 (26–35, 27L), gp100 (209–217, 210M), and Tyrosinase (368–376, 370D) In Adjuvant With PF-3512676 and GM-CSF In Metastatic Melanoma
- (2012) Ahmad A. Tarhini et al. JOURNAL OF IMMUNOTHERAPY
- A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer
- (2011) C. Manegold et al. ANNALS OF ONCOLOGY
- Direct Effects of Type I Interferons on Cells of the Immune System
- (2011) S. Hervas-Stubbs et al. CLINICAL CANCER RESEARCH
- Transmembrane Mutations in Toll-like Receptor 9 Bypass the Requirement for Ectodomain Proteolysis and Induce Fatal Inflammation
- (2011) Maria L. Mouchess et al. IMMUNITY
- CD8α+ Dendritic Cells Are the Critical Source of Interleukin-12 that Controls Acute Infection by Toxoplasma gondii Tachyzoites
- (2011) Mona Mashayekhi et al. IMMUNITY
- Immune Signaling by RIG-I-like Receptors
- (2011) Yueh-Ming Loo et al. IMMUNITY
- Randomized Phase III Trial of Paclitaxel/Carboplatin With or Without PF-3512676 (Toll-Like Receptor 9 Agonist) As First-Line Treatment for Advanced Non–Small-Cell Lung Cancer
- (2011) Vera Hirsh et al. JOURNAL OF CLINICAL ONCOLOGY
- Host type I IFN signals are required for antitumor CD8+T cell responses through CD8α+dendritic cells
- (2011) Mercedes B. Fuertes et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Type I interferon is selectively required by dendritic cells for immune rejection of tumors
- (2011) Mark S. Diamond et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Cutting Edge: A TLR9 Cytoplasmic Tyrosine Motif Is Selectively Required for Proinflammatory Cytokine Production
- (2011) A. Chockalingam et al. JOURNAL OF IMMUNOLOGY
- A Point Mutation in the Amino Terminus of TLR7 Abolishes Signaling without Affecting Ligand Binding
- (2011) Carlo Iavarone et al. JOURNAL OF IMMUNOLOGY
- Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study
- (2011) A. Carpentier et al. NEURO-ONCOLOGY
- The Structural Biology of Toll-like Receptors
- (2011) Istvan Botos et al. STRUCTURE
- Pattern Recognition Receptors and Inflammation
- (2010) Osamu Takeuchi et al. CELL
- In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study
- (2010) Joshua D. Brody et al. JOURNAL OF CLINICAL ONCOLOGY
- The Immunostimulatory Activity of Unmethylated and Methylated CpG Oligodeoxynucleotide Is Dependent on Their Ability To Colocalize with TLR9 in Late Endosomes
- (2010) S. D. de Jong et al. JOURNAL OF IMMUNOLOGY
- Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma
- (2010) Youn H. Kim et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Integrin CD11b negatively regulates TLR-triggered inflammatory responses by activating Syk and promoting degradation of MyD88 and TRIF via Cbl-b
- (2010) Chaofeng Han et al. NATURE IMMUNOLOGY
- The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors
- (2010) Taro Kawai et al. NATURE IMMUNOLOGY
- Slc15a4, AP-3, and Hermansky-Pudlak syndrome proteins are required for Toll-like receptor signaling in plasmacytoid dendritic cells
- (2010) A. L. Blasius et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Bifurcation of Toll-Like Receptor 9 Signaling by Adaptor Protein 3
- (2010) M. Sasai et al. SCIENCE
- Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein-
- (2010) M. Kraman et al. SCIENCE
- Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma
- (2009) Jeffrey S. Weber et al. CANCER
- Chemokine Expression in Melanoma Metastases Associated with CD8+ T-Cell Recruitment
- (2009) H. Harlin et al. CANCER RESEARCH
- Phase I study of TLR9 agonist PF-3512676 in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer
- (2009) Kazuhiko Yamada et al. CANCER SCIENCE
- Safety and Efficacy of PF-3512676 for the Treatment of Stage IV Renal Cell Carcinoma: An Open-Label, Multicenter Phase I/II Study
- (2009) John A. Thompson et al. Clinical Genitourinary Cancer
- Approaching the Asymptote: 20 Years Later
- (2009) Ruslan Medzhitov IMMUNITY
- Critical Role for Asparagine Endopeptidase in Endocytic Toll-like Receptor Signaling in Dendritic Cells
- (2009) Fernando E. Sepulveda et al. IMMUNITY
- Toll-Like Receptor 9-Dependent Activation of Myeloid Dendritic Cells by Deoxynucleic Acids from Candida albicans
- (2009) A. Miyazato et al. INFECTION AND IMMUNITY
- Tumor-reactive CD8+T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide® ISA-51: Association with survival
- (2009) Julia Karbach et al. INTERNATIONAL JOURNAL OF CANCER
- IFN- Enhances Peptide Vaccine-Induced CD8+ T Cell Numbers, Effector Function, and Antitumor Activity
- (2009) A. G. Sikora et al. JOURNAL OF IMMUNOLOGY
- Bacterial recognition by TLR7 in the lysosomes of conventional dendritic cells
- (2009) Giuseppe Mancuso et al. NATURE IMMUNOLOGY
- TAG, a splice variant of the adaptor TRAM, negatively regulates the adaptor MyD88–independent TLR4 pathway
- (2009) Eva M Palsson-McDermott et al. NATURE IMMUNOLOGY
- TLR9 traffics through the Golgi complex to localize to endolysosomes and respond to CpG DNA
- (2008) Annapoorani Chockalingam et al. IMMUNOLOGY AND CELL BIOLOGY
- The Crystal Structure of the Human Toll-like Receptor 10 Cytoplasmic Domain Reveals a Putative Signaling Dimer
- (2008) Tomas Nyman et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Randomized Phase II Trial of a Toll-Like Receptor 9 Agonist Oligodeoxynucleotide, PF-3512676, in Combination With First-Line Taxane Plus Platinum Chemotherapy for Advanced-Stage Non–Small-Cell Lung Cancer
- (2008) Christian Manegold et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 1 Evaluation of Intralesionally Injected TLR9-agonist PF-3512676 in Patients With Basal Cell Carcinoma or Metastatic Melanoma
- (2008) Maja A. Hofmann et al. JOURNAL OF IMMUNOTHERAPY
- Immunization With Analog Peptide in Combination With CpG and Montanide Expands Tumor Antigen-specific CD8+ T Cells in Melanoma Patients
- (2008) Julien Fourcade et al. JOURNAL OF IMMUNOTHERAPY
- The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor
- (2008) Sarah E. Ewald et al. NATURE
- Proteolytic cleavage in an endolysosomal compartment is required for activation of Toll-like receptor 9
- (2008) Boyoun Park et al. NATURE IMMUNOLOGY
- Toll-like receptor 9 (TLR9) agonists in the treatment of cancer
- (2008) A M Krieg ONCOGENE
- Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy
- (2007) Ronald J Buckanovich et al. NATURE MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search